Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Efficacy and Safety of Exenatide Once-Weekly Injection Compared to Once-Daily Insulin in Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* present with type 2 diabetes mellitus~* HbA1c between 7.1% and 11.0% inclusive~* body mass index (BMI) of \>18kg/m2 and \<35kg/m2, inclusive~* treated with a stable dose regimen of either of biguanide (BG) alone, BG + thiazolidinedione (TZD), BG + sulfonylurea (SU), or BG + TZD + SU for 90 days prior to study start~Exclusion Criteria:~* Have received chronic (\>14 consecutive days) systemic adrenocorticosteroid therapy by oral, intravenous, or intramuscular route or intraarticular steroid injection within 4 weeks prior to study start.~* Have been treated with drugs that promote weight loss within 90 days prior to study start.~* Have been treated with drugs that directly affect gastrointestinal motility for \> 21 consecutive days within 90 days prior to study start.~* Have had prior exposure to exenatide BID or QW or participated in the clinical trial of exenatide BID or QW (including the case that the study drug was not administered).~* Have been treated for \>2 consecutive weeks with any of the following excluded medications within 90 days prior to study start: Insulin, Dipeptidyl peptidase-4 (DPP-4) inhibitors, GLP-1 analogs~* Have received treatment within 30 days prior to study start drug that has not received regulatory approval for any indication.~* Are currently enrolled in any other clinical study or participated in and completed the clinical study within 30 days prior to study start.~* Have donated blood within 30 days prior to study start.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- exenatide once weekly (Type: EXPERIMENTAL): None
- insulin glargine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).